

Innovating and Access : Alternative R&D Models

K M Gopakumar

TWN

Problem with the Patent Lead R&D Model

- Compromises access
- Market failure

Problem of 90/10

- Little R&D funding to meet the health needs of developing countries
- MSF Study : Only 1% of the 1,400 new medicines created in the last 25 years were developed for the treatment of tropical disease. (1975-2025)
- DNDI MSF Study : 2000-11 only 4 NCEs out of approved for Neglected Diseases i.e. 1%

Unmet Needs

- New medicines/diagnostics/devices
- FDCs
- Modified dosage
- Adaptation to local needs

R&D Financing for Neglected Diseases

- Les involvement of pharmaceutical TNCS
- Project Development Partnerships
- Public Sector and Foundation Funding

Guiding Principles for R&D

- Innovation and access based on principle of delinkage
- R&D Models to achieve delinkage
 - Grant
 - Prizes
 - Advance marketing commitment
 - Milestone payment
 - Open innovation

WHO Process

- GSOPA
- CEWG Report and Recommendation
 - R&D Treaty for coordination, prioritization and Financing
- UN High level panel on A2M
 - R&D Treaty

WHO State of Play

- CEIPI
- R&D Blue Print
- Demonstration project

Scope for Activism

- International
- National